Renal Targeting Delivery Systems

Yuan, Zhixiang; Shang, Zhenghui; Jian, Gu; He, Lili

doi:10.4155/fmc-2019-0152

Cited by 10 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To achieve targeted drug delivery for AKI, nanotechnology-based approaches have been developed and can be categorized into two types: passive targeting and active targeting. Passive targeting relies on the intrinsic physicochemical characteristics of nanomaterials, such as size and surface charge, to selectively accumulate in the kidneys. , In active targeting, nanoparticles are designed to include some specific assistant ligands that can help recognize and bind to certain receptors on the surface of particular cell types, so as to enhance the specific uptake. These delivery approaches minimize nonspecific uptake by organs, allowing for selective drug delivery to the inflammatory injury sites in the kidneys.…”

Section: Strategy To Enhance the Therapeutic Property Of Nanomaterialsmentioning

confidence: 99%

Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury

Ba,

Ye,

Shang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a serious clinical syndrome with high morbidity, elevated mortality, and poor prognosis, commonly considered a “sword of Damocles” for hospitalized patients, especially those in intensive care units. Oxidative stress, inflammation, and apoptosis, caused by the excessive production of reactive oxygen species (ROS), play a key role in AKI progression. Hence, the investigation of effective and safe antioxidants and inflammatory regulators to scavenge overexpressed ROS and regulate excessive inflammation has become a promising therapeutic option. However, the unique physiological structure and complex pathological alterations in the kidneys render traditional therapies ineffective, impeding the residence and efficacy of most antioxidant and anti-inflammatory small molecule drugs within the renal milieu. Recently, nanotherapeutic interventions have emerged as a promising and prospective strategy for AKI, overcoming traditional treatment dilemmas through alterations in size, shape, charge, and surface modifications. This Review succinctly summarizes the latest advancements in nanotherapeutic approaches for AKI, encompassing nanozymes, ROS scavenger nanomaterials, MSC-EVs, and nanomaterials loaded with antioxidants and inflammatory regulator. Following this, strategies aimed at enhancing biocompatibility and kidney targeting are introduced. Furthermore, a brief discussion on the current challenges and future prospects in this research field is presented, providing a comprehensive overview of the evolving landscape of nanotherapeutic interventions for AKI.

show abstract

Section: Strategy To Enhance the Therapeutic Property Of Nanomaterialsmentioning

confidence: 99%

Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury

Ba,

Ye,

Shang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…42,[45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] Notably, rational design of nanoparticle size and charge can be leveraged to bypass certain physiological barriers and instruct nanoparticle accumulation into specific tissues like the lymph nodes. [60][61][62] As shown in Figure 3, nanocarriers designed for lymph node delivery must (1) avoid clearance from the bloodstream by the mononuclear phagocyte system (MPS), (2) extravasate out of fenestrated blood vessels, and (3) traverse the extracellular matrix of the interstitium. 63 Hence, a deep understanding of each of these physiological barriers and the size and charge constraints they place on nanoparticle design are critical to develop successful nanocarrier systems to the lymph nodes.…”

Section: Physiological Barriers To Lymph Node Drug Deliverymentioning

confidence: 99%

Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes

Trac

Chung

2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

The lymph nodes are major sites of cancer metastasis and immune activity, and thus represent important clinical targets. Although not as well-studied compared to subcutaneous administration, intravenous drug delivery is advantageous for lymph node delivery as it is commonly practiced in the clinic and has the potential to deliver therapeutics systemically to all lymph nodes. However, rapid clearance by the mononuclear phagocyte system, tight junctions of the blood vascular endothelium, and the collagenous matrix of the interstitium can limit the efficiency of lymph node drug delivery, which has prompted research into the design of nanoparticle-based drug delivery systems. In this mini review, we describe the physiological and biological barriers to lymph node targeting, how they inform nanoparticle design, and discuss the future outlook of lymph node targeting.

show abstract

“…c-MYB regulates the processes of self-renewal and differentiation, preventing the differentiation of cells [5,37,72,[74][75][76]. On the other hand, surface markers specific to tumor stem cells have not been established in renal tumors; however, it has been proposed that CXCR4 is essential for the maintenance of renal tumor stem cells [77], and it could be a good candidate as a specific marker of tumor stem cells [78][79][80]. Taken together, the reduction in the expression of MYBBP1A induces the activation of c-MYB, which ultimately results in an increase in the tumor stem cell phenotype.…”

Section: Mybbp1a and Cancermentioning

confidence: 99%

The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness

Felipe‐Abrio

Carnero

2020

Cancers

View full text Add to dashboard Cite

The MYB binding protein 1A (MYBBP1A, also known as p160) acts as a co-repressor of multiple transcription factors involved in many physiological processes. Therefore, MYBBP1A acts as a tumor suppressor in multiple aspects related to cell physiology, most of them very relevant for tumorigenesis. We explored the different roles of MYBBP1A in different aspects of cancer, such as mitosis, cellular senescence, epigenetic regulation, cell cycle, metabolism plasticity and stemness. We especially reviewed the relationships between MYBBP1A, the inhibitory role it plays by binding and inactivating c-MYB and its regulation of PGC-1α, leading to an increase in the stemness and the tumor stem cell population. In addition, MYBBP1A causes the activation of PGC-1α directly and indirectly through c-MYB, inducing the metabolic change from glycolysis to oxidative phosphorylation (OXPHOS). Therefore, the combination of these two effects caused by the decreased expression of MYBBP1A provides a selective advantage to tumor cells. Interestingly, this only occurs in cells lacking pVHL. Finally, the loss of MYBBP1A occurs in 8%–9% of renal tumors. tumors, and this subpopulation could be studied as a possible target of therapies using inhibitors of mitochondrial respiration.

show abstract

Renal Targeting Delivery Systems

Abstract: Despite much progress achieved in the SPs design, unexpectedly low targeting efficiency, retention and poor cell permeability are still the major obstacles in the development of SPs candidates "

Cited by 10 publications

References 20 publications

Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury

Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury

Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes

The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness

Contact Info

Product

Resources

About